Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 6, 2015, Pages 541-551

  Basu, Sanjay ^a,d,f   Bendavid, Eran ^a,b,c,e   Sood, Neeraj ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of General Medical Disciplines   (United States)

^c STANFORD UNIVERSITY   (United States)

^d NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cost effectiveness; developing countries; health policy; healthcare economics and organizations; insurance; myocardial infarction; stroke

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DISEASE SIMULATION; FEMALE; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART INFARCTION; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST CONTROL; DEVELOPING COUNTRY; ECONOMIC MODEL; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HEALTH CARE DELIVERY; INSURANCE; MORTALITY; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; RISK FACTOR; TERTIARY PREVENTION; TIME FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIA; INSURANCE COVERAGE; INSURANCE, HEALTH; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE; PREVENTIVE HEALTH SERVICES; PRIMARY PREVENTION; PROCESS ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SECONDARY PREVENTION; TERTIARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84947759476     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.115.001994     Document Type: Article

References (50)

1. Alwan A. Global status report on noncommunicable diseases 2010. [Internet]. World Health Organization; 2011 [cited 2015 Jan 28]. http://www.cabdirect.org/abstracts/20113168808.html. Accessed July 31, 2015.
2. McKee M, Balabanova D, Basu S, Ricciardi W, Stuckler D. Universal health coverage: A quest for all countries but under threat in some. Value Health. 2013;16(1 suppl):S39-S45. doi: 10.1016/j.jval.2012.10.001.
3. Evans DB, Etienne C. Health systems financing and the path to universal coverage. Bull World Health Organ. 2010;88:402. doi: 10.2471/BLT.10.078741.
4. Ortegón M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e607. doi: 10.1136/bmj.e607.
5. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370:2054-2062. doi: 10.1016/S0140-6736(07)61699-7.
6. Megiddo I, Chatterjee S, Nandi A, Laxminarayan R. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: A modeling study. Glob Heart. 2014;9:391-398.e3. doi: 10.1016/j.gheart.2014.07.002.
7. Gaziano T, Srinath Reddy K, Paccaud F, Horton S, Chaturvedi V. Chapter 33: Cardiovascular disease [Internet]. Disease control priorities in developing countries. World Bank Publications; 2006 [cited 2015 May 11]. https://books.google.com/books?hl=en&lr=&id=Ds93H98Z6D0C&oi =fnd&pg=PR7&dq=gaziano+cost+effectiveness+disease+control+prio rities&ots=rhz-WQYCi6&sig=qQQTKsD4TF5kA3TWZHKPZJ0ylj0. Accessed July 31, 2015.
8. Basu S, Millett C. Social epidemiology of hypertension in middle-income countries: determinants of prevalence, diagnosis, treatment, and control in the WHO SAGE study. Hypertension. 2013;62:18-26. doi: 10.1161/HYPERTENSIONAHA.113.01374.
9. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
10. Kopjar B, Sales AE, Piñeros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106-1108. doi: 10.1016/j.amjcard.2003.07.008.
11. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-Term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461. doi: 10.1016/S1062-1458(02)00914-5.
12. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-Term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212. doi: 10.1161/CIRCULATIONAHA.105.505636.
13. Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring oneyear compliance to antihypertension medication in the Seychelles. Bull World Health Organ. 2002;80:33-39.
14. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet. 2011;378:1231-1243. doi: 10.1016/S0140-6736(11)61215-4.
15. Sood N, Bendavid E, Mukherji A, Wagner Z, Nagpal S, Mullen P. Government health insurance for people below poverty line in India: quasi-experimental evaluation of insurance and health outcomes. BMJ. 2014;349:g5114.
16. Reddy S, Mary I. Rajiv Aarogyasri Community Health Insurance Scheme in Andhra Pradesh, India: A comprehensive analytic view of private public partnership model. Indian J Public Health. 2013;57:254-259. doi: 10.4103/0019-557X.123264.
17. Kowal P, Chatterji S, Naidoo N, Biritwum R, Fan W, Lopez Ridaura R, Maximova T, Arokiasamy P, Phaswana-Mafuya N, Williams S, Snodgrass JJ, Minicuci N, DEste C, Peltzer K, Boerma JT; SAGE Collaborators. Data resource profile: The World Health Organization Study on global AGEing and adult health (SAGE). Int J Epidemiol. 2012;41:1639-1649. doi: 10.1093/ije/dys210.
18. Shah B, Kumar N, Menon G, Khurana S, Kumar H. Assessment of Burden of Non-Communicable Diseases. Delhi: WHO India; 2010.
19. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, Calabria B, Chen H, Chugh SS, Cooley R, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, Davis A, Degenhardt L, Díaz-Torné C, Dorsey ER, Driscoll T, Edmond K, Elbaz A, Ezzati M, Feigin V, Ferri CP, Flaxman AD, Flood L, Fransen M, Fuse K, Gabbe BJ, Gillum RF, Haagsma J, Harrison JE, Havmoeller R, Hay RJ, Hel-Baqui A, Hoek HW, Hoffman H, Hogeland E, Hoy D, Jarvis D, Karthikeyan G, Knowlton LM, Lathlean T, Leasher JL, Lim SS, Lipshultz SE, Lopez AD, Lozano R, Lyons R, Malekzadeh R, Marcenes W, March L, Margolis DJ, McGill N, McGrath J, Mensah GA, Meyer AC, Michaud C, Moran A, Mori R, Murdoch ME, Naldi L, Newton CR, Norman R, Omer SB, Osborne R, Pearce N, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Pourmalek F, Prince M, Rehm JT, Remuzzi G, Richardson K, Room R, Saha S, Sampson U, Sanchez-Riera L, Segui-Gomez M, Shahraz S, Shibuya K, Singh D, Sliwa K, Smith E, Soerjomataram I, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Taylor HR, Tleyjeh IM, van der Werf MJ, Watson WL, Weatherall DJ, Weintraub R, Weisskopf MG, Whiteford H, Wilkinson JD, Woolf AD, Zheng ZJ, Murray CJ, Jonas JB. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129-2143. doi: 10.1016/S0140-6736(12)61680-8.
20. Management Sciences for Health. International drug price indicator guide [Internet]. Cambridge, MA: Management Sciences for Health; 2014 [cited 2015 Jan 28]
21. WHO. Choosing interventions that are cost effective (WHO-CHOICE) [Internet]. 2014. http://www.who.int/choice/cost-effectiveness/en/. Accessed July 31, 2015.
22. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: A cost-effectiveness analysis. Lancet. 2006;368:679-686. doi: 10.1016/S0140-6736(06)69252-0.
23. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ. 2003;326:1427. doi: 10.1136/bmj.326.7404.1427.
24. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-Term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
25. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774. doi: 10.1016/0140-6736(90)90878-9.
26. The Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: A meta-Analysis of individual patient data. Lancet. 2014;384:591-598. doi: 10.1016/S0140-6736(14)61212-5.
27. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-Analysis. BMJ. 2003;326:1423. doi: 10.1136/bmj.326.7404.1423.
28. Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-Analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590. doi: 10.1016/S0140-6736(12)60367-5.
29. Antithrombotic Trialists (ATT) Collaboration; Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-Analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860. doi: 10.1016/j.jvs.2009.11.069.
30. Antithrombotic Trialists Collaboration. Collaborative meta-Analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. doi: 10.1136/bmj.324.7329.71.
31. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment. Lancet. 2004;363:768-774.
32. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514. doi: 10.1016/S0140-6736(04)15692-4.
33. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119(1 suppl):300S-320S.
34. World Health Organization. WHO Global InfoBase. Geneva: WHO; 2014.
35. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD III, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA III, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stöckl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260. doi: 10.1016/S0140-6736(12)61766-8.
36. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2?7 million participants. Lancet. 2011;378:31-40. doi: 10.1016/S0140-6736(11)60679-X.
37. Tobacco Free Initiative. Global Adult Tobacco Survey (GATS) India Report 2009-2010. Geneva: WHO; 2011.
38. Basu S, Babiarz KS, Ebrahim S, Vellakkal S, Stuckler D, Goldhaber-Fiebert JD. Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ. 2013;347:f6048.
39. Basu S, Glantz S, Bitton A, Millett C. The effect of tobacco control measures during a period of rising cardiovascular disease risk in India: A mathematical model of myocardial infarction and stroke. PLoS Med. 2013;10:e1001480. doi: 10.1371/journal.pmed.1001480.
40. United Nations Population Division. World Population Prospects: The 2012 Revision. United Nations: United Nations Population Division; 2013.
41. Bhopal R, Fischbacher C, Vartiainen E, Unwin N, White M, Alberti G. Predicted and observed cardiovascular disease in South Asians: Application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf). 2005;27:93-100. doi: 10.1093/pubmed/fdh202.
42. World Health Organization. Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings. Geneva: WHO; 2013.
43. World Health Organization. Prevention of Recurrent Heart Attacks and Strokes in Low and Middle Income Populations: Evidence Based Recommendations for Policy-Makers and Health Professionals. Geneva: WHO; 2013.
44. Mannucci E, Dicembrini I, Lauria A, Pozzilli P. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care. 2013;36(suppl 2):S259-S263. doi: 10.2337/dcS13-2018.
45. Salomon JA, Carvalho N, Gutiérrez-Delgado C, Orozco R, Mancuso A, Hogan DR, Lee D, Murakami Y, Sridharan L, Medina-Mora ME, González-Pier E. Intervention strategies to reduce the burden of noncommunicable diseases in Mexico: cost effectiveness analysis. BMJ. 2012;344:e355.
46. Srivastava A, Mohanty SK. Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PLoS One. 2013;8:e62134. doi: 10.1371/journal.pone.0062134.
47. Krumholz HM, Wang Y, Chen J, Drye EE, Spertus JA, Ross JS, Curtis JP, Nallamothu BK, Lichtman JH, Havranek EP, Masoudi FA, Radford MJ, Han LF, Rapp MT, Straube BM, Normand SL. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA. 2009;302:767-773. doi: 10.1001/jama.2009.1178.
48. World Bank. World Development Indicators. Washington, DC: IBRD; 2014.
49. Moran AE, Tzong KY, Forouzanfar MH, Rothy GA, Mensah GA, Ezzati M, Murray CJ, Naghavi M. Variations in ischemic heart disease burden by age, country, and income: The Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart. 2014;9:91-99. doi: 10.1016/j.gheart.2013.12.007.
50. Gaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events? JAMA. 2014;312:2503-2504. doi: 10.1001/jama.2014.16047.